A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy (MM17)
收藏数据链接：
官方服务：
资源简介：
HeSANDA 1.0.0
创建时间：
2023-06-07
